MoonLake Immunotherapeutics Earnings Call Transcripts
Fiscal Year 2026
-
Regulatory clarity enables BLA submission for SLK in HS with strong efficacy and safety data, while S-OLARIS and VELA programs show leading clinical outcomes and long-term benefits. Financial position supports ongoing development and commercial launch preparations.
Fiscal Year 2025
-
Sonelokimab showed robust efficacy and safety in phase 3 HS trials, with strong patient-reported outcomes and a favorable safety profile. Despite a high placebo response in one trial, management is confident in regulatory approval and market competitiveness, supported by a strong financial position.
-
Sonelokimab's phase III HS program completed rapid recruitment with strong baseline alignment to prior pivotal trials, supporting high confidence in efficacy replication. The company is well-funded, targeting a large, underpenetrated market, and differentiates through efficacy, convenience, and safety. Commercial focus is on the US, with ex-US options open.
Fiscal Year 2024
-
Sonelokimab is advancing through multiple late-stage trials in HS, PsA, and new indications, with strong efficacy data and a projected peak sales opportunity exceeding $8 billion. The company is well-funded, executing on an ambitious clinical plan, and expects major data readouts in 2025–2026, targeting a 2027 U.S. launch.